Nyxthracis (previously Obiltoxaximab SFL) Evrópusambandið - íslenska - EMA (European Medicines Agency)

nyxthracis (previously obiltoxaximab sfl)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - Ónæmiskerfið sera og mótefni, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Síprox Tafla 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

síprox tafla 250 mg

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 250 mg

Síprox Tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

síprox tafla 500 mg

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 500 mg

Sativex Munnholsúði, lausn 27 mg/ml + 25 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sativex munnholsúði, lausn 27 mg/ml + 25 mg/ml

jazz pharmaceuticals ireland ltd - delta-9-tetrahydrocannabinolum; cannabidiolum inn - munnholsúði, lausn - 27 mg/ml + 25 mg/ml